My Companies
Notification
Account
Log Out
Login
Dr. Reddy's received U.S. FDA approval for its rituximab biosimilar, to be exclusively commercialized by Fresenius Kabi. The approval follows a successful pre-license inspection and strengthens the company's growing global biosimilars portfolio.
Dr. Reddy's Announces API And Services CEO Resignation After 23 Years
Dr Reddy's Receives US FDA Form 483 With Seven Observations At Biologics Plant
Dr. Reddy's Biologics Plant Receives US FDA Form 483 With Seven Observations
Dr. Reddy's Receives USFDA Form 483 With Seven Observations at Biologics Plant